We are live on
!
Find out more
GA
General Atlantic Portfolio holdings
AUM
$2.91B
1-Year Est. Return
24.21%
This Fund
S&P 500
This Quarter
Est. Return
+13.04%
1 Year Est. Return
+24.21%
3 Year Est. Return
+168.27%
5 Year Est. Return
+91.75%
10 Year Est. Return
+1,020.11%
AUM
$2.87B
AUM Growth
-$458M
(-14%)
Cap. Flow
-$613M
Cap. Flow
% of AUM
-21.35%
Top 10 Holdings %
Top 10 Hldgs %
98.97%
Holding
17
New
1
Increased
2
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nurix Therapeutics
NRIX
|
+$70.4M |
| 2 |
CHYM
Chime Financial
CHYM
|
+$43.6M |
| 3 |
Revolution Medicines
RVMD
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$272M |
| 2 |
Alignment Healthcare
ALHC
|
+$200M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$90.3M |
| 4 |
BULL
Webull Corp
BULL
|
+$71.9M |
| 5 |
Royalty Pharma
RPRX
|
+$52.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 52.16% |
| 2 | Healthcare | 33.17% |
| 3 | Financials | 12.93% |
| 4 | Consumer Staples | 1.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
dLocal
DLO
$4.42B
| $660M | 22.97% |
46,656,695
| – | – |
|
|
CHYM
2
Chime Financial
CHYM
$12.6B
| $535M | 18.63% |
21,259,683
+2,050,923
| +11% | +$43.6M |
|
3
XP
XP
$8.96B
| $372M | 12.93% |
22,699,133
-2,818,600
| -11% | -$49.6M |
|
4
Alkami Technology
ALKT
$2.16B
| $277M | 9.63% |
11,991,480
| – | – |
|
|
5
Alignment Healthcare
ALHC
$2.83B
| $260M | 9.05% |
13,167,733
-11,119,494
| -46% | -$200M |
|
|
6
Revolution Medicines
RVMD
$44.6B
| $224M | 7.8% |
2,812,928
+338,500
| +14% | +$22.2M |
|
7
Pharvaris
PHVS
$2.48B
| $223M | 7.76% |
8,031,252
| – | – |
|
|
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
| $153M | 5.33% |
6,117,715
-3,564,103
| -37% | -$90.3M |
|
|
9
Nurix Therapeutics
NRIX
$2.72B
| $92.9M | 3.23% |
+4,897,159
| New | +$70.4M |
|
|
EWCZ
10
DELISTED
European Wax Center
EWCZ
| $47.2M | 1.64% |
13,110,492
| – | – |
|
11
Riskified
RSKD
$833M
| $26.5M | 0.92% |
5,324,998
| – | – |
|
12
Grove Collaborative
GROV
$42.7M
| $2.72M | 0.09% |
2,474,859
| – | – |
|
|
BULL
13
Webull Corp
BULL
$4.96B
| $395K | 0.01% |
50,816
-7,148,051
| -99% | -$71.9M |
|
|
ADAG
14
Adagene
ADAG
$247M
| – | – |
-3,782,339
| Closed | -$7.53M |
|
|
AKRO
15
DELISTED
Akero Therapeutics
AKRO
| – | – |
-5,733,989
| Closed | -$272M |
|
|
16
Royalty Pharma
RPRX
$27.1B
| – | – |
-1,500,000
| Closed | -$52.9M |
|
|
ALMS
17
Alumis Inc
ALMS
$2.9B
| – | – |
-1,297,530
| Closed | -$5.18M |
|
Similar funds
LSA
ACM
SCM
HWA
BWL
ISS
7WCP
JC
General Atlantic's Q4 2025 Portfolio in Review
As of Q4 2025, General Atlantic held 17 positions worth $2.87B, down 14% from $3.33B the previous quarter. Its ten largest holdings account for 99% of the portfolio.
General Atlantic withdrew a net $613M in Q4 2025, closing 4 positions and reducing 4 holdings. Its most notable exit was Akero Therapeutics, an estimated $272M position sold in full.
By sector, the portfolio is most concentrated in Technology at 52% of assets, up from 45% a quarter earlier, followed by Healthcare and Financials.
Against the trend, General Atlantic opened a new position in Nurix Therapeutics worth $92.9M.
- General Atlantic's largest Q4 2025 buy was Nurix Therapeutics: 4,897,159 shares worth $92.9M.
- General Atlantic added most to Chime Financial in Q4 2025, an estimated $43.6M increase.
- General Atlantic's biggest Q4 2025 reduction was Alignment Healthcare, cutting an estimated $200M.
- General Atlantic fully exited Akero Therapeutics in Q4 2025, selling an estimated $272M.
- General Atlantic's ten largest holdings make up 99% of its $2.87B portfolio in Q4 2025.
- General Atlantic opened 1 new position and closed 4 in Q4 2025.
- General Atlantic's portfolio value fell 14% quarter-over-quarter to $2.87B.
Based on General Atlantic's 13F filing for Q4 2025, filed 17 Feb 2026.